Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, PD, Safety and Tolerability of SR1375 in Healthy Subjects
NCT05421923Phase 1Completed
- Sponsor
- Shanghai SIMRD Biotechnology Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pneumonia comparing SR1375 capsules with Placebo (2 arms). Primary endpoints: Maximum Plasma Concentration at Day 54, Time to Maximum Concentration at Day 54 and 4 more. Started Jun 2022; status: completed.
02
Drugs
SR1375
03
Conditions
pneumonia
Beyond the preview
Go deeper on NCT05421923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05421923.